thalidomide / Generic mfg. - LARVOL DELTA

5-Year Sustained Minimal Residual Disease (MRD) Negativity and Survival With Daratumumab Maintenance (D-Maint) in Transplant-Eligible (TE) NDMM: CASSIOPEIA Registry (IMS 2026) - "Introduction: CASSIOPEIA showed daratumumab, bortezomib, thalidomide, dexamethasone ( DVTd ) induction/autologous stem cell transplantation/consolidation improved outcomes vs VTd in TE - NDMM. After >8.5 y m FU with 96% retention, CASSIOPEIA registry data confirm deep and durable benefit of daratumumab tx . DVTd reduced risk of progression vs VTd by 38% and mortality by 39%. D - m aint demonstrated prolonged m PFS and PFS2 vs OBS ."

Clinical • Minimal residual disease • Residual disease • Transplantation

ADVANCED COMBINATION THERAPY OF UPADACITINIB AND GUSELKUMAB FOR INTESTINAL BEHCET'S DISEASE – A CASE REPORT (UEGW 2026) - "She failed or was intolerant to adalimumab, infliximab, tacrolimus, thalidomide, and ustekinumab. DTT may be effective in refractory intestinal BD after failure of advanced therapies. Inhibiting IL-23 and JAK–STAT signaling may provide effective disease control and steroid-sparing benefits. Further studies are needed to define the safety of combination biologic and small molecule therapy in this population."

Case report • Clinical • Combination therapy • Metastases • Immunology • Rare Diseases • IL23A

WHEN EVERYTHING FAILS: MANAGEMENT OF REFRACTORY SMALL BOWEL BLEEDING USING THALIDOMIDE (UEGW 2026) - "Multiple endoscopic therapies were performed, including argon plasma coagulation, hemoclip placement, and endoscopic hemostatic powder application.Despite repeated endoscopic interventions and monthly octreotide LAR (20–30 mg), the patient remained transfusion-dependent with persistent severe bleeding. This case highlights the complexity of refractory small bowel bleeding and supports thalidomide as an effective and safe therapeutic option after failure of endoscopic, surgical, and medical treatments."

Hematological Disorders

PAZOPANIB AS RESCUE THERAPY FOR REFRACTORY GASTROINTESTINAL BLEEDING IN PATIENTS WITH HAEMOSTATIC DISORDERS: A CASE SERIES (UEGW 2026) - "Pazopanib is an oral tyrosine kinase inhibitor with a better safety profile compared to other agents such as thalidomide or bevacizumab. In this serie, pazopanib was associated with a substantial reduction in GIB and transfusion requirements, with an acceptable safety profile. These findings support the potential role for pazopanib as a rescue therapy for refractory GIB. Larger prospective studies are needed to establish the role, the optimal dosing strategies, and long-term safety of pazopanib in refractory GIB."

Clinical • Cardiomyopathy • Cardiovascular • Gastroenterology • Hematological Disorders • Hemophilia

CRBN-independent hypnotic effects of thalidomide derivatives (Neuroscience 2026) - "Sci. USA., 117, 23106-23112 (2020)."

CNS Disorders • CRBN

Clinical Insights into RELA-Associated Disease: From Genotype to Phenotype and Exploring Treatment. (PubMed, Genes (Basel)) - "In the present family, the proband presented with early-onset Behçet-like intestinal inflammation and achieved clinical and endoscopic remission after thalidomide and dose-escalated infliximab treatment. This study expands the clinical spectrum of RELA-associated disease and highlights preliminary variant-related clinical patterns that require confirmation in larger independent cohorts. The available treatment experience suggests that TNF blockade may be considered as a therapeutic option in selected patients, although comparative efficacy cannot be established from the available data."

Journal • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Oncology • Vitiligo • RELA

Announcement of Awards: William Dameshek Prize, Janet Rowley Basic Science Medal, and Helen M. Ranney Clinical and Translational Science Medal (ASH 2026) - "His research identified the mechanism of action for thalidomide, lenalidomide, and related molecules for multiple myeloma and a subtype of myelodysplastic syndromes. Building upon this work, he codeveloped and led clinical trials on BH3 mimetics, including the first in-human clinical trial of venetoclax and first venetoclax combination trials for chronic lymphocytic leukemia and lymphoma. His pioneering research established a novel class of targeted therapies, BCL2 inhibitors, which have fundamentally reshaped the treatment landscape for patients with hematologic malignancies."

Clinical • First-in-human • IO biomarker • Chronic Lymphocytic Leukemia • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Sickle Cell Disease • Targeted Protein Degradation

LASSBio-753 as a new prototype of anti-tumor necrosis factor-alpha anti-inflammatory drug. (PubMed, Biomed Pharmacother) - "In addition, it reduced the number of abdominal contractions and the duration of paw licking that were chemically induced. The results obtained demonstrate that LASSBio-753 possesses significant anti-inflammatory and antinociceptive potential and may be a promising candidate for the treatment of inflammatory diseases; however, studies in inflammatory disease models are needed to better elucidate its therapeutic potential."

Journal • Inflammation • Oncology • Pain • IL1B • MPO • TNFA

Pseudo-Heyde Syndrome: Severe Hypertrophic Obstructive Cardiomyopathy Causing Recurrent GI Bleeding (ACG 2026) - "First-line treatment generally involves endoscopic therapy, with adjunctive options including octreotide and thalidomide...We propose that severe HOCM may produce a âpseudo-Heyde syndrome,â predisposing patients to recurrent GI angioectasias through a similar pathophysiologic mechanism. Recognition of this association is important, as treatment should focus not only on controlling GI bleeding but also on management of the underlying cardiac pathology."

Cardiomyopathy • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hemophilia • Hypertension • Hypertrophic Cardiomyopathy • Myocardial Infarction • Nephrology • Obstructive Hypertrophic Cardiomyopathy • Renal Disease

Efficacy and Safety of Pharmacological Therapies for Gastrointestinal Angiodysplasia Bleeding: A Systematic Review and Meta-Analysis (ACG 2026) - "29 studies (SSA: 12 studies; hormonal therapy: 6; thalidomide: 6; antiangiogenics: 5) comprising 746 patients were included. The pooled positive treatment response rate was 71.3% (95% CI 61.9-80.0%; I2=76.8%). Mean hemoglobin improved by 2.96 g/dL (CI 2.20-3.71; I2=93.8%) and blood transfusion requirements decreased by a mean of 7.6 units (CI 5.38-9.9; I2= 99%)."

Retrospective data • Review • Cardiovascular • Gastroenterology

An Ascitic Mystery: Unmasking Sclerosing Mesenteritis (ACG 2026) - "Given the patientâs persistent symptoms and negative workup for malignancy or TB, empiric treatment for suspected SM was initiated with prednisone and tamoxifen...Alternative agents such as azathioprine, pentoxifylline, cyclophosphamide, and thalidomide have also been used with varying success. Obstructive symptoms need conservative therapy or surgical bypass if necessary. Figure: CT image depicting partially calcified sclerosing mesenteritis mass"

Cardiovascular • Fibrosis • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Neuroendocrine Tumor • Respiratory Diseases • Solid Tumor • Tuberculosis

Treatment Modalities and Reported Clinical Outcomes in Oral Crohn's Disease: A Systematic Review (ACG 2026) - "Other commonly reported initial therapies included triamcinolone (n=17; response 10/17), azathioprine (n=16; response 8/16), prednisone (n=14; response 3/14), and adalimumab (n=12; response 10/12). A total of 217 patients from 66 articles (52 case reports, 14 case series) published between 1975-2025 were selected for analysis. Endoscopy/biopsy was the most common diagnostic modality (170 reports), followed by clinical examination (106). Among initial treatment modalities, infliximab was the most frequently reported therapy (n=19), with symptomatic response in 14/19 evaluable cases."

Clinical • Clinical data • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Thalidomide Versus Octreotide After Endoscopic Intervention for Bleeding From GIAD and GAVE: A Systematic Review and Meta-Analysis of Clinical Response and Rebleeding Recurrence Compared to Placebo or Supportive Care (ACG 2026) - "Seven studies were included, including five randomized controlled trials. Pharmacologic therapy significantly improved clinical response compared with placebo or supportive care (RD 0.376, 95% CI 0.183-0.570) and reduced rebleeding recurrence (RD -0.423, 95% CI -0.517 to -0.329). The pooled response rate across five cohorts was 66.6% (95% CI 59.6-73.7%)."

Retrospective data • Review • Cardiovascular • Gastroenterology • Gastrointestinal Disorder

Comparison of Relapse Rate and Disease Severity among patients with Type 2 Lepra Reaction receiving Tofacitinib and Thalidomide separately as an adjuvant to systemic steroids: A Longitudinal Analytical Study (EADV 2026) - No abstract available

Clinical • Infectious Disease

Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up. (PubMed, Leuk Res Rep) - "We report a case of refractory T-LGL leukemia complicated by PRCA that was resistant to cyclosporine (CsA). Then the patient achieved rapid disease control with chidamide plus thalidomide in the early phase, and has maintained long-term remission for six years on chidamide monotherapy after thalidomide discontinuation. Notably, clonal T-cell receptor (TCR) variable β-chain (Vβ) 3 persisted on flow cytometry throughout the treatment course. As an epigenetic modulator, chidamide represents a more convenient and promising therapeutic strategy for managing T-LGL leukemia, prompting us to present this case."

Journal • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • T-Cell Large Granular Lymphocyte Leukemia

Current Paradigm Shift in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Narrative Review. (PubMed, Cerebrovasc Dis) - "Antiangiogenic agents including intravenous bevacizumab, pomalidomide, thalidomide, and oral pazopanib have demonstrated efficacy in reducing bleeding severity, improving hemoglobin levels, and decreasing transfusion requirements in moderate-to-severe disease. Advances in antiangiogenic and precision-medicine approaches are improving bleeding control and long-term outcomes. Early recognition, comprehensive screening, individualized therapy, and coordinated management across specialties are critical for optimizing care in this complex multisystem disease."

Journal • Review • Cardiovascular • CNS Disorders • Gastroenterology • Hematological Disorders • ACVRL1 • ALK1 • ENG • SMAD4 • TGFB1

Second Primary Malignancies After Autologous Transplantation for Multiple Myeloma in the Modern Treatment Era: Incidence, Risk Factors, and Prognostic Impact Using a Competing-Risk Approach (IMS 2026) - " We conducted a retrospective single-center study of 2,420 patients with MM who underwent upfront auto-HSCT following induction therapy that included at least one modern agent (bortezomib, lenalidomide, thalidomide, or carfilzomib). SPMs represent a relatively common late complication after auto-HSCT and independently confer a substantial adverse impact on long-term survival. Although competing mortality from MM remains higher, these findings highlight the importance of long-term surveillance and survivorship-focused risk assessment in MM patients undergoing auto-HSCT."

Clinical • Acute Myelogenous Leukemia • Basal Cell Carcinoma • Bladder Cancer • Bone Marrow Transplantation • Breast Cancer • Genetic Disorders • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Leukemia • Lung Cancer • Multiple Myeloma • Myelodysplastic Syndrome • Non-melanoma Skin Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Thoracic Cancer • Transplantation

Real-World Outcomes of Anti-Cd38-Based Quadruplet Induction Regimens in Newly Diagnosed Multiple Myeloma: A Multinational Latin American Experience. (IMS 2026) - "Frontline regimens included Daratumumab combined with bortezomib, lenalidomide and dexamethasone (D-VRd) in 59%; Daratumumab, bortezomib, thalidomide, dexamethasone (D-VTd) in 36% and Isatuximab CUADS in 5%...However, 1% of collections failed despite plerixafor use in 55% of patients... In this large real-word Latin America experience, anti-CD38-quadruplet induction demonstrated high response depth, frequent MRD negativity, successful stem cell mobilization, and favorable survival outcomes with manageable toxicity. These findings support the feasibility and effectiveness of quadruplet-based strategies for transplant-eligible NDMM patients in Latin America."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Renal Disease • CD34

A Novel Analytical Approach to Addressing the Challenge of Assessing Overall Survival in Myeloma Trials in the Context of a Rapidly Evolving Treatment Landscape (IMS 2026) - "Between 2013 and 2016, 1056 patients were randomised between cyclophosphamide, thalidomide, and dexamethasone (CTD), cyclophosphamide, lenalidomide, and dexamethasone (CRD) or carfilzomib, cyclophosphamide, lenalidomide and dexamethasone (KCRD). At trial outset first relapse options included thalidomide, lenalidomide or bortezomib combinations... This work provides a novel application of TSE in order to disentangle the effect of subsequent treatments on OS. In this example, if all patients received subsequent mAB the trial OS difference narrows. This is important for ongoing trials, especially in newly diagnosed populations, as current advances in myeloma therapy to include bispecific antibody therapies at relapse will impact OS treatment effects."

Clinical • Hematological Malignancies • Multiple Myeloma

Long-Term Follow-Up of Busulfan Plus Cyclophosphamide and Etoposide Versus High-Dose Melphalan as Conditioning in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma (IMS 2026) - " A total of 35 patients with multiple myeloma, enrolled between March 2016 and September 2021, patients aged 47-67 (median 57 years) with multiple myeloma were enrolled to receive bortezomib, thalidomide and dexamethasone (VTD) induction followed by ASCT. Our study showed that BuCyE is an effective and well-tolerated alternative to HDMEL conditioning, with good PFS."

Hematological Malignancies • Multiple Myeloma • Transplantation

Evaluation of Triple-Class Exposed Patients in a Brazilian Referral Center (IMS 2026) - "Among penta-refractory patients, 70.6% were classified as such because of refractoriness to both thalidomide and lenalidomide, reflecting limited access to lenalidomide in the Brazilian public healthcare system. This study describes the clinical characteristics and outcomes of triple-class exposed patients in a Brazilian referral center. Differences from global reports were observed, particularly those related to limited access to key therapies, including lenalidomide in the public healthcare system."

Clinical • Hematological Malignancies • Multiple Myeloma

Elevated APOBEC3B Expression Marks Functionally High-Risk Multiple Myeloma with Early Failure of Frontline Pi/Imid Therapy (IMS 2026) - " RNA-sequencing data from the CoMMpass cohort were analyzed in newly diagnosed MM patients treated with frontline PI/IMiD-based regimens, including bortezomib-, carfilzomib-, or ixazomib-based therapies combined with lenalidomide- or thalidomide-containing backbones, with or without ASCT. Elevated A3B expression defines a biologically aggressive, clinically high-risk MM subset associated with early failure of frontline PI/IMiD-based therapy and inferior survival. Convergent transcriptomic and functional analyses identify A3B as a clinically relevant biomarker linked to replication stress and chromosomal instability programs associated with early therapeutic failure in MM, warranting further evaluation in the anti-CD38 era."

IO biomarker • Hematological Malignancies • Multiple Myeloma • APOBEC3B • CHEK1 • RPA2

Aponermin+Kt-Decp, a Good Bridging Regimen for Relapsed/Refractory Multiple Myeloma with Extramedullary Disease (IMS 2026) - P | "Clinical trial information: NCT05013190 Apo-KT-DECP: Apo 10 mg/kg, days 1 – 3 and 15 – 18; carfilzomib: 27 mg/m ² , days 1 – 2, 8 – 9, 15 – 16; thalidomide: 100 mg, days 1 – 10 and 15 – 24; cisplatin, etoposide, cyclophosphamide, and dexamethasone at protocol-specified doses. Conclusion ： Our study demonstrates that PFS p rolong ed o bviously with less toxicity in RRMM with EMD . ORR of 2 -cycle was 86.2 %, could be a good choice as bridging regimen ."

Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Respiratory Diseases • Thrombocytopenia

Real-World Outcomes of First-Line Bortezomib, Thalidomide, and Dexamethasone for Multiple Myeloma in a Resource-Limited Setting (IMS 2026) - "ASCT was associated with significantly improved overall and progression-free survival and remained the only independent prognostic factor for overall survival in multivariable analysis. Despite most patients being transplant-eligible, fewer than half ultimately underwent ASCT, highlighting a substantial gap between transplant eligibility and access in this resource-limited setting."

Clinical • Late-breaking abstract • Real-world • Real-world evidence • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia • Plasmacytoma

Second Primary Malignancies After Autologous Transplantation for Multiple Myeloma in the Modern Treatment Era: Incidence, Risk Factors, and Prognostic Impact Using a Competing-Risk Approach (IMS 2026) - " We conducted a retrospective single-center study of 2,420 patients with MM who underwent upfront auto-HSCT following induction therapy that included at least one modern agent (bortezomib, lenalidomide, thalidomide, or carfilzomib). SPMs represent a relatively common late complication after auto-HSCT and independently confer a substantial adverse impact on long-term survival. Although competing mortality from MM remains higher, these findings highlight the importance of long-term surveillance and survivorship-focused risk assessment in MM patients undergoing auto-HSCT."

Clinical • Acute Myelogenous Leukemia • Basal Cell Carcinoma • Bladder Cancer • Bone Marrow Transplantation • Breast Cancer • Genetic Disorders • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Leukemia • Lung Cancer • Multiple Myeloma • Myelodysplastic Syndrome • Non-melanoma Skin Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Thoracic Cancer • Transplantation